Genmab — Februar 2021
-
Men som pensions investering er Genmab da SÅ meget en must have aktie. Det bliver den nye novo
-
yes, the difference with me is that i already translate those extra costs into extra revenue, where they don't. And i understand that it is much easier for them to just extrapolate these costs, while it is much harder to put a number on the revenues. For products that are still in early fases.
-
Jan plejer at give et indblik i hvor stor en andel af R&D udgifterne går til top 3 og top 10. Den fordeling blev ikke nævnt i går. Den savner jeg
-
EL desværre siger investerings niveauet som sådan ikke noget om at sandsynligheden for at komme på markedet er det større. Genmab og Abbvie er blot meget mere aggressive
for at hente Roche. Så det er nødvendigt med det sats -
Altså - investeringer skal selvfølgelig øge muligheden for at der kommer noget på markedet men marginalt er der faldende udbytte af udviklingsomkostningerne især når de går til acceleret udvikling. Du får meget mindre for 10 mia på et år end for 1 mia hvert år gennem 10 år.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind